ACORN CAPITAL ADVISORS, LLC
13F Reported Value
ⓘ$366.5M
Holdings
20
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
ACORN CAPITAL ADVISORS, LLC disclosed 20 positions worth $366.5M in its Form 13F-HR for Q2 2026, led by $CGON (CG Oncology, Inc.) at 21.9% of the equity portfolio, followed by $URGN and $TRVI. During the quarter the fund opened 1 new position and exited 3 — including a new stake in $ENGN and a full exit from $TERN. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from ACORN CAPITAL ADVISORS, LLC’s Form 13F-HR filing with the SEC under CIK 2054410.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 27.0#2,595
Quality
$80.4M1,131,500 sh - —
Quality
$61.6M1,673,420 sh - —
Quality
$40.0M2,144,844 sh - —
Quality
$36.0M3,497,948 sh - 53.8
Quality
$33.5M4,131,299 sh - —
Quality
$21.9M986,760 sh - —
Quality
$19.1M643,381 sh - 15.1
Quality
$14.8M1,518,113 sh - —
Quality
$12.9M2,839,674 sh - —
Quality
$10.2M1,540,266 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 CG Oncology, Inc.$CGON | 27.0#2,595 | $80.4M | 1,131,500 |
 UroGen Pharma Ltd.$URGN | — | $61.6M | 1,673,420 |
 Trevi Therapeutics, Inc.$TRVI | — | $40.0M | 2,144,844 |
 Candel Therapeutics, Inc.$CADL | — | $36.0M | 3,497,948 |
 PUMA BIOTECHNOLOGY, INC.$PBYI | 53.8 | $33.5M | 4,131,299 |
 Jade Biosciences, Inc.$JBIO | — | $21.9M | 986,760 |
 Bicara Therapeutics Inc.$BCAX | — | $19.1M | 643,381 |
 Karyopharm Therapeutics Inc.$KPTI | 15.1 | $14.8M | 1,518,113 |
 OnKure Therapeutics, Inc.$OKUR | — | $12.9M | 2,839,674 |
 CYBIN INC.$HELP | — | $10.2M | 1,540,266 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of ACORN CAPITAL ADVISORS, LLC's 20 positions.
Showing top 10 of 20 holdings.
Sector Allocation
Healthcare
$366.5M
Full Holdings — ACORN CAPITAL ADVISORS, LLC (Q2 2026)
All 20 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $CGON | CG Oncology, Inc. | $80.4M | 21.9% | +0% | 27 |
| 2 | $URGN | UroGen Pharma Ltd. | $61.6M | 16.8% | +0% | — |
| 3 | $TRVI | Trevi Therapeutics, Inc. | $40.0M | 10.9% | +0% | — |
| 4 | $CADL | Candel Therapeutics, Inc. | $36.0M | 9.8% | +0% | — |
| 5 | $PBYI | PUMA BIOTECHNOLOGY, INC. | $33.5M | 9.1% | +0% | 53.8 |
| 6 | $JBIO | Jade Biosciences, Inc. | $21.9M | 6.0% | +25% | — |
| 7 | $BCAX | Bicara Therapeutics Inc. | $19.1M | 5.2% | -0% | — |
| 8 | $KPTI | Karyopharm Therapeutics Inc. | $14.8M | 4.0% | +427% | 15.1 |
| 9 | $OKUR | OnKure Therapeutics, Inc. | $12.9M | 3.5% | +0% | — |
| 10 | $HELP | CYBIN INC. | $10.2M | 2.8% | +0% | — |
| 11 |  $TARA | Protara Therapeutics, Inc. | $6.7M | 1.8% | +0% | — |
| 12 |  $AURA | Aura Biosciences, Inc. | $6.6M | 1.8% | +56% | — |
| 13 |  $LONA | LeonaBio, Inc. | $5.8M | 1.6% | +0% | — |
| 14 |  $VSTM | Verastem, Inc. | $5.6M | 1.5% | +0% | 29.7 |
| 15 |  $WHWK | Whitehawk Therapeutics, Inc. | $5.2M | 1.4% | +0% | 26.4 |
| 16 |  $FIXX | Q32 Bio Inc. | $2.8M | 0.8% | -31% | 36.4 |
| 17 |  $ENGN | enGene Therapeutics Inc. | $2.2M | 0.6% | NEW | — |
| 18 |  $JSPR | Jasper Therapeutics, Inc. | $604,027 | 0.2% | +2% | — |
| 19 |  $BCAB | BioAtla, Inc. | $447,645 | 0.1% | -98% | — |
| 20 |  $YARW | Yarrow Bioscience, Inc. | $926 | 0.0% | +0% | — |
New Positions (1)
$ENGN enGene Therapeutics Inc.$2.2M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for ACORN CAPITAL ADVISORS, LLC including:
Track ACORN CAPITAL ADVISORS, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for ACORN CAPITAL ADVISORS, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: ACORN CAPITAL ADVISORS, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For ACORN CAPITAL ADVISORS, LLC (SEC CIK: 2054410), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in ACORN CAPITAL ADVISORS, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.